Public Interest in Psilocybin and Psychedelic Therapy in the Context of the COVID-19 Pandemic: Google Trends Analysis
Authors: Danias George , Appel Jacob 
Published: November 2023

Background

Psychedelic substances have demonstrated promise in the treatment of depression, anxiety, and substance use disorders. Significant media coverage has been dedicated to psychedelic medicine, but it is unclear whether the public associates psilocybin with its potential therapeutic benefits. The COVID-19 pandemic led to an increase in depression, anxiety, and substance abuse in the general population.

Objective

This study attempts to link increases in interest in these disorders with increases in interest in psilocybin using Google Trends.

Methods

Weekly interest-over-time Google Trends data for 4 years, from the week of March 11, 2018, to the week of March 6, 2022, were obtained for the following terms: “psilocybin,” “psychedelic therapy,” “cannabis,” “cocaine,” “antidepressant,” “depression,” “anxiety,” and “addiction.” Important psilocybin-related news and the declaration of the pandemic were noted. Trends data for each of the queried terms were plotted, and multiple regression analysis was performed to determine the slope of the prepandemic and postpandemic data with 95% CIs. Nonparametric Tau-U analysis was performed correcting for baseline trends. Results from this test were used to make inferences about the pre- and postpandemic trends and inferences about the change in overall level of searches between the 2 groups.

Results

Tau values for prepandemic data were significant for stable trends, all ranging –0.4 to 0.4. Tau values for postpandemic data showed positive trends for “psilocybin,” “psychedelic therapy,” and “antidepressant.” All other trends remained stable in the range of –0.4 to 0.4. When comparing Tau values for pre- and postpandemic data, overall increases in relative search volume (RSV) were seen for “psilocybin,” “psychedelic therapy,” and “anxiety,” and overall decreases in RSV were seen for “depression,” “addiction,” and “cocaine.” Overall RSVs for “cannabis” and “antidepressant” remained stable as Tau values ranged between –0.4 and 0.4. In the immediate aftermath of the declaration of the pandemic, drop-offs in interest were seen for all terms except for “anxiety” and “cannabis.” After the initial shock of a global pandemic, “psilocybin” and “psychedelic therapy” groups demonstrated increases in interest trends and overall RSV.

Conclusions

These data suggest that overall interest in “psilocybin” and “psychedelic therapy” increased at higher rates and to higher levels after than before the declaration of the pandemic. This is consistent with our hypothesis that interest increased for these treatments after the pandemic as incidence of depression, anxiety, and addiction increased. However, there may be other drivers of interest for these topics, since interest in antidepressants—the typical pharmacologic treatments for depression and anxiety—followed the expected pattern of drop-off and accelerated interest back to prepandemic levels. Interest in “psilocybin” and “psychedelic therapy” may have also been partially driven by popular culture hype and novelty, explaining why interest increased at a higher rate post pandemic and continued to grow, surpassing prior interest.